Group 1 - The presentation focuses on the Phase III ALLEGORY results for Gazyva in systemic lupus erythematosus (SLE), which were recently presented at SLEuro [2] - The agenda includes updates on the pipeline in immune-mediated kidney and rheumatological diseases, specifically mentioning the Gazyva development program and other B-cell depleting agents in development [3]

Core Perspective - The recent volatility in oil prices has raised questions about the stability of the market and the risk-on trade, but statistically, it has not derailed the overall market direction [2][3][15]. Oil Market Impact - Oil prices surged to $119 per barrel after hours but have since dropped below $95, indicating rapid market fluctuations [2]. - The ongoing geopolitical tensions, particularly related to the Iran war, have exacerbated concerns about the AI slowdown trade, presenting potential buying opportunities in tech stocks [6][15]. Technology Sector Insights - Large-cap tech stocks, particularly Nvidia, have seen a significant reduction in forward earnings multiples from 38 times to around 20-21 times, despite earnings growth exceeding 60% [5]. - The tech sector, especially companies involved in the AI supply chain, is viewed as a long-term opportunity despite short-term market shocks [6][10]. - The Russell 1000 growth index, which is 50% tech, indicates the importance of getting tech investments right for long-term success [10]. Specific Company Focus - Eli Lilly is highlighted as a strong investment due to its positioning in the GLP-1 and weight loss market, with expectations for its oral medication, Zepbound, to capture significant market share [14]. - The company has been held since 2021 and is seen as well-positioned compared to competitors like Novo [14]. Market Volatility and Future Outlook - The current market volatility is considered normal after three strong years of equity returns, particularly in technology [9]. - The messaging from the administration regarding geopolitical tensions will be crucial in determining market sentiment and risk appetite moving forward [15][16].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - March 9, 2026) ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth emerged [6].

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PomDoctor, Ltd. (NASDAQ:POM) and Inovio Pharmaceuticals, Inc. (NASDAQ:INO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. PomDoctor, Ltd. (NASDAQ:POM) Class Period: October 9, 2 ...

Question-and-Answer SessionMani ForooharLeerink Partners LLC, Research Division I'm happy to have you. All are welcome. Let's chat a little bit. I know we spoke over breakfast this morning on some of these issues. So it's a little bit repetitive, you'll have to forgive me. But let's dive into where we are on the ongoing TRYNGOLZA launch and the transition to what's going to be an sHTG launch over the course of this year, but involves a little bit of label change, tinkering with pricing, contracting. Like ho ...

West Pharma CEO Eric Green to retire after 11 years at the helm | ReutersSkip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv- CompaniesWest Pharmaceutical Services IncFollowMarch 9 (Reuters) - West Pharmaceutical's (WST.N), opens new tab chief executive Eric Green said on Monaday he plans to retire once the company finds his successor, ending an 11- year run at the helm.The Pennsylvania-based company said the transition is expected in the second ...

Summary of Ionis Pharmaceuticals Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: 2026 Global Healthcare Conference - **Date**: March 09, 2026 Key Points Ongoing Product Launches - **TRYNGOLZA Launch**: The company is transitioning from the TRYNGOLZA launch to the upcoming SHTG launch, involving label changes and pricing adjustments [2][6] - **2025 Performance**: 2025 was a pivotal year with TRYNGOLZA achieving $108 million in product revenue, exceeding estimates [7] - **SHTG Patient Population**: Severe hypertriglyceridemia (SHTG) is estimated to affect over 3 million people in the U.S., with 1 million at high risk for acute pancreatitis [8] Competitive Landscape - **Pricing Pressure**: A new competitor has entered the FCS market with a significantly lower price, leading to some pricing pressure for TRYNGOLZA [9] - **First-Mover Advantage**: The company believes it has a year to a year and a half head start over competitors for the SHTG market, which is crucial for capturing the high-risk patient population [17] Clinical Data and Efficacy - **Phase 3 Data**: The company reported an 85% reduction in acute pancreatitis and a 72% reduction in triglycerides on top of standard care, which is expected to drive physician enthusiasm [10][21] - **Liver Fat Observations**: A small but statistically significant increase in liver fat was observed in clinical studies, but it is not considered an adverse event and is expected to return to baseline over time [25][27] Market Opportunities - **U.S. Market Potential**: The peak product sales for TRYNGOLZA and SHTG in the U.S. have been increased to over $2 billion based on healthcare provider demand [11] - **International Expansion**: The company has partnered with Sobi for commercialization in Europe, focusing on the most severe patient populations [30] Future Developments - **CARDIO-TTRansform Study**: The company is looking forward to phase 3 data for cardiomyopathy, which could significantly expand its market presence [33] - **Lp(a) HORIZON Study**: Targeting Lp(a) with pelacarsen, the study is expected to achieve a 20%-25% relative risk reduction, representing a multi-billion dollar opportunity [43] Strategic Positioning - **Innovation Focus**: Ionis is committed to innovation in oligonucleotide therapeutics, with follow-on molecules in development for less frequent dosing and targeting CNS diseases [51][52] - **Competitive Strategy**: The company aims to maintain its leadership by focusing on product efficacy, safety, and innovative delivery methods [51] Additional Insights - **Market Dynamics**: The competitive landscape for oligonucleotide therapeutics is becoming more crowded, but Ionis plans to differentiate through innovation and first-mover advantages [50] - **Patient-Centric Approach**: The company emphasizes the importance of addressing unmet medical needs and ensuring patient access to treatments [11][30]

TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well tolerated BERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, presented data on TONMYATM (cyclobenzaprine HCl sublingua ...

TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well toleratedBERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, presented data on TONMYA™ (cyclobenzaprine HCl sublingual t ...